Skip to content

Analysis of Viral Reactivation and Prognosis in Hepatocellular Carcinoma Patients with Low HBV Viral Load After Systemic Treatment

To explore viral reactivation and prognosis in patients with hepatitis B low viral load HCC after systemic therapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101601
Enrollment
Unknown
Registered
2025-04-27
Start date
2024-09-30
Completion date
Unknown
Last updated
2025-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Observation group:NA

Sponsors

The Fifth Medical Center of the PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age>= 18 years, regardless of gender; 2. Evidence of liver cirrhosis confirmed by imaging, pathology, or liver stiffness measurement; 3. At least two imaging modalities, such as dynamic contrast-enhanced MRI or dynamic contrast-enhanced CT, showing typical features of hepatocellular carcinoma, combined with clinical diagnosis of primary liver cancer based on medical history and serological tests; 4. Availability of data on HBV-related indicators; 5. Liver function classified as Child-Pugh class A or B; 6. ECOG performance status score of 0-2.

Exclusion criteria

Exclusion criteria: 1. Presence of secondary malignant tumors in the liver; 2. Positive markers for other viral infections, including hepatitis A virus IgM antibodies, hepatitis C virus antibodies, hepatitis D virus IgG antibodies, hepatitis E virus IgM antibodies, or HIV antibodies; 3. Hematologic disorders or other serious conditions that significantly affect coagulation function; 4. Lack of HBV DNA testing and imaging evaluation data at the time of initial HCC treatment and during treatment; 5. Liver function classified as Child-Pugh class C; 6. ECOG performance status score of >= 3; 7. Pregnant women or female participants who do not use contraception; 8. Presence of severe cardiovascular, cerebrovascular, or other systemic diseases that are unstable or uncontrolled; 9. History of substance abuse or any medical, psychological, or social conditions that may affect the study, compromise participant compliance, or endanger participant safety; 10. Determination by the investigator that the participant is unsuitable for this study based on comprehensive judgment.

Design outcomes

Primary

MeasureTime frame
Hepatitis B virus load;

Secondary

MeasureTime frame
Imaging indicators;

Countries

China

Contacts

Public ContactYinying Lu

The Fifth Medical Center of the PLA General Hospital

lzpaxb@163.com+86 66933129

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026